---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-001844"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:38:25.091203+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q4 2024 net revenue $31.2M, first profitable quarter; H1 2025 guidance $50-60M

## Summary
- Q4 2024 net revenue $31.2M; net income $13.5M ($0.22/diluted share); adjusted EBITDA $15.3M.
- Full year 2024 net revenue $43.5M; net loss narrowed to $17.9M ($0.30/share) from $46.3M in 2023.
- Preliminary H1 2025 revenue guidance $50-60M (Q1 >$33M); cash operating expense guidance $72-78M reaffirmed.
- Cash and short-term investments $51.7M at Dec 31, 2024; expects >$75M at Q1 2025 end.
- Inpatient sales team with Syneos Health nearly complete; Phase 3 DefenCath TPN study to start Q2 2025.

## SEC filing metadata
- accession: 0001013762-25-001844
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/0001013762-25-001844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000101376225001844/ea0235520-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-001844
- JSON: https://secwatch.observer/filing/0001013762-25-001844.json
- Plain text: https://secwatch.observer/filing/0001013762-25-001844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.